FDA Restricts Sale of Essure Device, Requires That Patients Receive Risk Information Before Using Contraceptive Device
In its commitment to ensuring the post-market safety of medical devices, the FDA used their authority to impose a unique restriction on the sale and distribution of the permanent female contraceptive device Essure. Despite efforts to educate and inform both patients and doctors about the risks associated with the Essure device, the FDA became aware that many women were not receiving this important information.
In 2016, the FDA ordered Bayer, the manufacturer of Essure, to conduct a post-market survey of patients implanted with the device. This led to an order that Bayer must include a boxed warning and a patient decision checklist on the product labeling, which led to an approximately 70% decline in sales of Essure in the United States. Despite this, the FDA still feels that many patients are not receiving the information about risks before deciding upon implantation.
Every single woman receiving this device should fully understand the associated risks,” said FDA Commissioner Scott Gottlieb, M.D.
What Is Essure?
Essure is a permanently implanted birth control device. Essure is unique in that it is the only permanent birth control device that does not require a surgical incision. It was approved for use by the FDA in 2002. The device is deposited into the fallopian tubes via flexible coils inserted into the vagina and cervix. Over a period of three months, tissue forms around the device, creating a barrier that prevents sperm from reaching the eggs.
Risks Associated With The Essure Device
Some women have reported adverse events after implantation of the Essure device, including:
- Perforation of the uterus
- Perforation of the fallopian tubes
- Migration of the device to the abdominal cavity
- Migration of the device to the pelvic cavity
- Persistent pain
- Allergic or hypersensitivity reactions
- Weight changes
- Hair loss
- Mood changes